{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:07:53Z","timestamp":1790356073025,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10147-026-03125-9","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:35:46Z","timestamp":1783690546000},"page":"2260-2270","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Moderately hypofractionated intensity-modulated radiation therapy for intermediate- or high-risk prostate cancer: five-year results from a single-institution study in Japan"],"prefix":"10.1007","volume":"31","author":[{"given":"Wataru","family":"Anno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuri","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kunogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Kamima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuyo","family":"Kozuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Numao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Ebara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Yonese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"issue":"1","key":"3125_CR1","doi-asserted-by":"publisher","first-page":"e70043","DOI":"10.3322\/caac.70043","volume":"76","author":"RL Siegel","year":"2026","unstructured":"Siegel RL, Kratzer TB, Wagle NS et al (2026) Cancer statistics. CA Cancer J Clin 76(1):e70043. https:\/\/doi.org\/10.3322\/caac.70043","journal-title":"CA Cancer J Clin"},{"key":"3125_CR2","unstructured":"Cancer Statistics Cancer Information Service, National Cancer Center, Japan (National Cancer Registry, Ministry of Health, Labour and Welfare). https:\/\/ganjoho.jp\/reg_stat\/statistics\/data\/dl\/index.html [Accessed 4 April 2026]"},{"key":"3125_CR3","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Prostate Cancer. Version 5 (2026) https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf [Accessed 4 April 2026]"},{"issue":"10","key":"3125_CR4","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1001\/jama.294.10.1233","volume":"294","author":"AL Zietman","year":"2005","unstructured":"Zietman AL, DeSilvo ML, Slater JD et al (2005) Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294(10):1233\u20131239. https:\/\/doi.org\/10.1001\/jama.294.10.1233","journal-title":"JAMA"},{"issue":"13","key":"3125_CR5","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1200\/JCO.2005.05.2530","volume":"24","author":"ST Peeters","year":"2006","unstructured":"Peeters ST, Heensbergen WD, Koper PC et al (2006) Dose response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24(13):1990\u20131996. https:\/\/doi.org\/10.1200\/JCO.2005.05.2530","journal-title":"J Clin Oncol"},{"issue":"6","key":"3125_CR6","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S1470-2045(07)70143-2","volume":"8","author":"DP Dearnaley","year":"2007","unstructured":"Dearnaley DP, Sydes MR, Graham JD et al (2007) Escalated-dose versus standard dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomized controlled trial. Lancet Oncol 8(6):475\u2013487. https:\/\/doi.org\/10.1016\/S1470-2045(07)70143-2","journal-title":"Lancet Oncol"},{"issue":"34","key":"3125_CR7","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1200\/JCO.18.01097","volume":"36","author":"SC Morgan","year":"2018","unstructured":"Morgan SC, Hoffman K, Loblaw DA et al (2018) Hypofractionated radiation therapy for localized prostate cancer: an ASTRO, ASCO, and AUA evidence-based guideline. J Clin Oncol 36(34):3411\u20133430. https:\/\/doi.org\/10.1200\/JCO.18.01097","journal-title":"J Clin Oncol"},{"issue":"8","key":"3125_CR8","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","volume":"17","author":"D Dearnaley","year":"2016","unstructured":"Dearnaley D, Syndikus I, Mossop H et al (2016) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 17(8):1047\u20131060. https:\/\/doi.org\/10.1016\/S1470-2045(16)30102-4","journal-title":"Lancet Oncol"},{"issue":"8","key":"3125_CR9","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/S1470-2045(16)30070-5","volume":"17","author":"L Incrocci","year":"2016","unstructured":"Incrocci L, Wortel RC, Alemayehu WG et al (2016) Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 17(8):1061\u20131069. https:\/\/doi.org\/10.1016\/S1470-2045(16)30070-5","journal-title":"Lancet Oncol"},{"issue":"17","key":"3125_CR10","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","volume":"35","author":"CN Catton","year":"2017","unstructured":"Catton CN, Lukka H, Gu CS et al (2017) Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol 35(17):1884\u20131890. https:\/\/doi.org\/10.1200\/JCO.2016.71.7397","journal-title":"J Clin Oncol"},{"issue":"20","key":"3125_CR11","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","volume":"34","author":"WR Lee","year":"2016","unstructured":"Lee WR, Dignam JJ, Amin MB et al (2016) Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol 34(20):2325\u20132332. https:\/\/doi.org\/10.1200\/JCO.2016.67.0448","journal-title":"J Clin Oncol"},{"issue":"6","key":"3125_CR12","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s10147-024-02517-z","volume":"29","author":"K Nakamura","year":"2024","unstructured":"Nakamura K, Nihei K, Saito Y et al (2024) A Japanese multi-institutional phase II study of moderate hypofractionated intensity-modulated radiotherapy with image-guided technique for prostate cancer. Int J Clin Oncol 29(6):847\u2013852. https:\/\/doi.org\/10.1007\/s10147-024-02517-z","journal-title":"Int J Clin Oncol"},{"key":"3125_CR13","doi-asserted-by":"publisher","unstructured":"Roach M 3rd, Hanks G, Thames H Jr et al (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65(4):965\u2013974. https:\/\/doi.org\/10.1016\/j.ijrobp.2006.04.029","DOI":"10.1016\/j.ijrobp.2006.04.029"},{"issue":"12","key":"3125_CR14","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1001\/jamaoncol.2023.4267","volume":"9","author":"JB Yu","year":"2023","unstructured":"Yu JB, Sun Y, Jia AY et al (2023) Increasing use of shorter-course radiotherapy for prostate cancer. JAMA Oncol 9(12):1696\u20131701. https:\/\/doi.org\/10.1001\/jamaoncol.2023.4267","journal-title":"JAMA Oncol"},{"issue":"1","key":"3125_CR15","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1093\/jrr\/rraf082","volume":"67","author":"T Ikawa","year":"2026","unstructured":"Ikawa T, Morishima T, Nakata K et al (2026) Trends in hypofractionated radiotherapy use among patients with breast or prostate cancer: a multicenter study in Osaka, Japan. J Radiat Res 67(1):104\u2013113. https:\/\/doi.org\/10.1093\/jrr\/rraf082","journal-title":"J Radiat Res"},{"issue":"3","key":"3125_CR16","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/S1470-2045(14)70482-6","volume":"16","author":"S Aluwini","year":"2015","unstructured":"Aluwini S, Pos F, Schimmel E et al (2015) Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial. Lancet Oncol 16(3):274\u2013283. https:\/\/doi.org\/10.1016\/S1470-2045(14)70482-6","journal-title":"Lancet Oncol"},{"issue":"4","key":"3125_CR17","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S1470-2045(15)00567-7","volume":"17","author":"S Aluwini","year":"2016","unstructured":"Aluwini S, Pos F, Schimmel E et al (2016) Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. Lancet Oncol 17(4):464\u2013474. https:\/\/doi.org\/10.1016\/S1470-2045(15)00567-7","journal-title":"Lancet Oncol"},{"issue":"20","key":"3125_CR18","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1200\/JCO.23.02445","volume":"42","author":"WR Lee","year":"2024","unstructured":"Lee WR, Dignam JJ, Amin MB et al (2024) Long-term analysis of NRG Oncology RTOG 0415: a randomized phase III noninferiority study comparing two fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol 42(20):2377\u20132381. https:\/\/doi.org\/10.1200\/JCO.23.02445","journal-title":"J Clin Oncol"},{"key":"3125_CR19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ctro.2022.11.001","volume":"38","author":"S Wang","year":"2022","unstructured":"Wang S, Tang W, Luo H et al (2022) The role of image-guided radiotherapy in prostate cancer: a systematic review and meta-analysis. Clin Transl Radiat Oncol 38:81\u201389. https:\/\/doi.org\/10.1016\/j.ctro.2022.11.001","journal-title":"Clin Transl Radiat Oncol"},{"issue":"5","key":"3125_CR20","doi-asserted-by":"publisher","first-page":"100902","DOI":"10.1016\/j.adro.2022.100902","volume":"7","author":"LS Rowe","year":"2022","unstructured":"Rowe LS, Mandia JJ, Salerno KE et al (2022) Bowel and bladder reproducibility in image guided radiation therapy for prostate cancer: results of a patterns of practice survey. Adv Radiat Oncol 7(5):100902. https:\/\/doi.org\/10.1016\/j.adro.2022.100902","journal-title":"Adv Radiat Oncol"},{"issue":"5","key":"3125_CR21","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.ijrobp.2015.04.030","volume":"92","author":"N Mariados","year":"2015","unstructured":"Mariados N, Sylvester J, Shah D et al (2015) Hydrogel spacer prospective multicenter randomized controlled pivotal trial: dosimetric and clinical effects of perirectal spacer application in men undergoing prostate image guided intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys 92(5):971\u2013977. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.04.030","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"3125_CR22","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1001\/jamaoncol.2022.7592","volume":"9","author":"NF Mariados","year":"2023","unstructured":"Mariados NF, Orio PF 3rd, Schiffman Z et al (2023) Hyaluronic acid spacer for hypofractionated prostate radiation therapy: a randomized clinical trial. JAMA Oncol 9(4):511\u2013518. https:\/\/doi.org\/10.1001\/jamaoncol.2022.7592","journal-title":"JAMA Oncol"},{"issue":"3","key":"3125_CR23","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.ijrobp.2009.02.025","volume":"76","author":"SL Gulliford","year":"2010","unstructured":"Gulliford SL, Foo K, Morgan RC et al (2010) Dose\u2013volume constraints to reduce rectal side effects from prostate radiotherapy: evidence from MRC RT01 Trial ISRCTN 47772397. Int J Radiat Oncol Biol Phys 76(3):747\u2013754. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.02.025","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"3125_CR24","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.ijrobp.2020.01.003","volume":"106","author":"A Wilkins","year":"2020","unstructured":"Wilkins A, Naismith O, Brand D et al (2020) Derivation of dose\/volume constraints for the anorectum from clinician- and patient-reported outcomes in the CHHiP trial of radiation therapy fractionation. Int J Radiat Oncol Biol Phys 106(5):928\u2013938. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.01.003","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03125-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03125-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03125-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:50:27Z","timestamp":1790355027000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03125-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3125"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03125-9","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"15 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Moderately hypofractionated IMRT for prostate cancer.","order":2,"name":"Ethics","label":"Short running","group":{"name":"EthicsHeading","label":"Declarations"}}]}}